Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoffer Clemmensen

Showing results (61-70 of 108) with videos related to

Pageof 11
Sort By:
Nature|March 28, 2014
FXR is a molecular target for the effects of vertical sleeve gastrectomyKaren K Ryan, Valentina Tremaroli, Christoffer Clemmensen, et al.
Molecular Metabolism|March 1, 2024
Atlas of exercise-induced brain activation in miceGrethe Skovbjerg, Andreas Mæchel Fritzen, Charlotte Sashi Aier Svendsen, et al.
The Journal of Endocrinology|April 1, 2025
Deletion of GFRAL blunts weight lowering effects of FGF21 in female miceAlberte Silke Buch-Rasmussen, Helle Andersen, Christina Stage, et al.
British Journal of Cancer|April 14, 2022
RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminomaChristine Hjorth Andreassen, Mette Lorenzen, John E Nielsen, et al.
Nature Communications|February 8, 2024
Protection against overfeeding-induced weight gain is preserved in obesity but does not require FGF21 or MC4RCamilla Lund, Pablo Ranea-Robles, Sarah Falk, et al.
Molecular Metabolism|October 1, 2016
Fibroblast activation protein (FAP) as a novel metabolic targetMiguel Angel Sánchez-Garrido, Kirk M Habegger, Christoffer Clemmensen, et al.
Diabetes|January 1, 2014
GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic dietChristoffer Clemmensen, Joseph Chabenne, Brian Finan, et al.
Molecular Metabolism|July 17, 2024
Dietary medium-chain fatty acids reduce hepatic fat accumulation via activation of a CREBH-FGF21 axisYe Cao, Masaya Araki, Yoshimi Nakagawa, et al.
Diabetes|July 1, 2025
Sustained Weight Loss With Combined LEAP2 and Semaglutide Treatment in MiceStephanie K Holm, Valdemar B I Johansen, Pablo Ranea-Robles, et al.
Endocrinology|March 30, 2022
Beta-Hydroxybutyrate Suppresses Hepatic Production of the Ghrelin Receptor Antagonist LEAP2Stephanie Holm, Anna S Husted, Louise J Skov, et al.
Pageof 11

Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
Nature|March 28, 2014
FXR is a molecular target for the effects of vertical sleeve gastrectomyKaren K Ryan, Valentina Tremaroli, Christoffer Clemmensen, et al.
Molecular Metabolism|March 1, 2024
Atlas of exercise-induced brain activation in miceGrethe Skovbjerg, Andreas Mæchel Fritzen, Charlotte Sashi Aier Svendsen, et al.
The Journal of Endocrinology|April 1, 2025
Deletion of GFRAL blunts weight lowering effects of FGF21 in female miceAlberte Silke Buch-Rasmussen, Helle Andersen, Christina Stage, et al.
British Journal of Cancer|April 14, 2022
RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminomaChristine Hjorth Andreassen, Mette Lorenzen, John E Nielsen, et al.
Nature Communications|February 8, 2024
Protection against overfeeding-induced weight gain is preserved in obesity but does not require FGF21 or MC4RCamilla Lund, Pablo Ranea-Robles, Sarah Falk, et al.
Molecular Metabolism|October 1, 2016
Fibroblast activation protein (FAP) as a novel metabolic targetMiguel Angel Sánchez-Garrido, Kirk M Habegger, Christoffer Clemmensen, et al.
Diabetes|January 1, 2014
GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic dietChristoffer Clemmensen, Joseph Chabenne, Brian Finan, et al.
Molecular Metabolism|July 17, 2024
Dietary medium-chain fatty acids reduce hepatic fat accumulation via activation of a CREBH-FGF21 axisYe Cao, Masaya Araki, Yoshimi Nakagawa, et al.
Diabetes|July 1, 2025
Sustained Weight Loss With Combined LEAP2 and Semaglutide Treatment in MiceStephanie K Holm, Valdemar B I Johansen, Pablo Ranea-Robles, et al.
Endocrinology|March 30, 2022
Beta-Hydroxybutyrate Suppresses Hepatic Production of the Ghrelin Receptor Antagonist LEAP2Stephanie Holm, Anna S Husted, Louise J Skov, et al.
Pageof 11